The Life Sciences Report Asks If It Is Time to Go

SAN FRANCISCO, CA --(Marketwired - January 23, 2017) - Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics Inc. ( NASDAQ : BCLI ), including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases.

Included in this article is: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics is a biopharmaceutical company developing adult stem cell-based therapies for a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and Parkinson's disease (PD). The company's NurOwn® technology is based on the use of mesenchymal stem cells (MSCs), engineered ex vivo, to express increased amount of neurotrophic factors (NTFs). The company has tested single-dose treatments of NurOwn in ALS patients in two Phase 1/2 clinical trials and most recently in a randomized, double-blind, placebo-controlled Phase 2 clinical trial.

BrainStorm's proprietary NurOwn technology uses a novel differentiation protocol such that mesenchymal stem cells (MSCs) are converted into neurotrophic factor-secreting cells (MSC-NTF cells). MSCs are a type of pluripotent adult stem cell that can become many different cell types, including cartilage, bone and fat. MSCs are located in various tissues throughout the body; for BrainStorm's technology, the cells are harvested from the patient's bone marrow. Following isolation, the cells are cultured ex vivo in a series of specialized growth mediums in order to induce production of NTFs. These MSC-NTF cells are then re-administered to the patient through either intramuscular (IM) or intrathecal (IT) injections, or both.

Continue reading this article: Time to Go Long on BrainStorm Cell Therapeutics?

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURE:

The following companies paid Streetwise Reports to issues a press release on their behalf relating to this article: BrainStorm Cell Therapeutics Inc. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

Please see the end of the article for the complete disclosure: Time to Go Long on BrainStorm Cell Therapeutics?